|Day's range||10.00 - 10.00|
CRISPR Therapeutics (NASDAQ: CRSP) is heading for an important moment: the potential approval of its first product, exa-cel to treat blood disorders. First, let's talk a little bit about CRISPR's technology. In T1D, the body destroys islet cells that normally would control blood sugar levels.
Vertex Pharmaceuticals (NASDAQ: VRTX) has made a fortune developing medicines for cystic fibrosis (CF), a rare disease that causes damage to the lungs. The company is awaiting approval for exa-cel -- a therapy for the blood disorder sickle cell disease -- which it developed in combination with CRISPR Therapeutics. Recently, these two longtime partners announced a new deal to target another disease, type 1 diabetes (T1D).
The market has kept investors on a rollercoaster ride over the past year, and the choppy waters may continue for some time to come. No one can predict when smooth waters may be here to stay, particularly given the ongoing economic volatility that's affecting the current investing environment. Here are two such stocks to consider buying in the near future, regardless of whether another full-fledged bear market appears in 2023.